Total Body HIIT Program for Age-Related Sarcopenia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Creighton University, Omaha, NE
Age-Related Sarcopenia+1 More
Total Body HIIT Program - Other
Eligibility
65+
All Sexes
What conditions do you have?
Select

Study Summary

This study will examine differences in a 12 week high-intensity interval training regimen. The Total Body HIIT program incorporates a resistance (circuit) and an anaerobic (bike) component in older adults. The specific objectives focus on examining cardiovascular endurance, neuromuscular function, and muscle architecture.

Eligible Conditions

  • Age-Related Sarcopenia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Age-Related Sarcopenia

Study Objectives

10 Primary · 8 Secondary · Reporting Duration: change from baseline to immediately after the HIIT intervention

change from baseline to immediately after the HIIT intervention
Change in 6-Min Walk Test performance from baseline to following HIIT intervention
Change in Balance: Berg Balance Scale from baseline to following HIIT intervention
Change in Balance: Center of Pressure Excursion from baseline to following HIIT intervention
Change in Balance: Functional Gait Assessment from baseline to following HIIT intervention
Change in Evoked Muscle Function Assessments: Evoked Peak Force from baseline to following HIIT intervention
Change in Evoked Muscle Function Assessments: Evoked Peak Rate of Force Development from baseline to following HIIT intervention
Change in Functional Lower Body Strength from baseline to following HIIT intervention
Change in Functional Upper Body Strength from baseline to following HIIT intervention
Change in Gait Speed from baseline to following HIIT intervention
Change in Health-Related Quality of Life from baseline to following HIIT intervention
Change in Muscle Biopsy-based Muscle Architecture from baseline to following HIIT intervention
Change in Rate of Muscle Activation from baseline to following HIIT intervention
Change in Ultrasound-based Muscle Architecture: Cross-sectional Area from baseline to following HIIT intervention
Change in Ultrasound-based Muscle Architecture: Echo Intensity from baseline to following HIIT intervention
Change in V02 peak from baseline to following HIIT intervention
Change in Voluntary Electromechanical Delay from baseline to following HIIT intervention
Change in Voluntary Muscle Strength Tests (Isokinetics) from baseline to following HIIT intervention
Change in Voluntary Muscle Strength Tests (Isometrics) from baseline to following HIIT intervention

Trial Safety

Safety Progress

1 of 3

Other trials for Age-Related Sarcopenia

Trial Design

1 Treatment Group

Total Body HIIT Program
1 of 1
Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: Total Body HIIT Program · No Placebo Group · N/A

Total Body HIIT Program
Other
Experimental Group · 1 Intervention: Total Body HIIT Program · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: change from baseline to immediately after the hiit intervention
Closest Location: Creighton University · Omaha, NE
Photo of Omaha  1Photo of Omaha  2Photo of Omaha  3
2000First Recorded Clinical Trial
1 TrialsResearching Age-Related Sarcopenia
89 CompletedClinical Trials

Eligibility Criteria

Age 65+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are 65 years of age or older.
You have received a physician's clearance to participate in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.